A5007580310- Lymphoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Chronic Myeloid Leukemia Treatments
- Education, Psychology, and Social Research
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Retirement, Disability, and Employment
- Cutaneous lymphoproliferative disorders research
- Myasthenia Gravis and Thymoma
- Educational Methods and Teacher Development
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Multiple Myeloma Research and Treatments
- Sexual Differentiation and Disorders
- Art Therapy and Mental Health
- Child Therapy and Development
- Cancer Risks and Factors
- Enterobacteriaceae and Cronobacter Research
- Global Trade and Competitiveness
- Bone fractures and treatments
- Cardiac tumors and thrombi
- Hematological disorders and diagnostics
- Frailty in Older Adults
- Birth, Development, and Health
Hospitais da Universidade de Coimbra
2019-2022
University of Coimbra
2022
Therapy with Tyrosine Kinase Inhibitors (TKI) aiming stable deep molecular response is the gold standard to treat Chronic Myeloid Leukemia (CML). NKT-like cells (CD3+CD56+) combine characteristics of T and NK cells. The physiopathological role these remains unknown although literature refers their association inflammation, autoimmune diseases, cancer. Since information regarding in CML rare, we aimed at characterization patients treated TKIs. Peripheral blood from 48 40 healthy donors were...
Interim response evaluation by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET) in diffuse large B cell lymphoma (DLBCL) could be important to rule out disease progression and has been suggested predictive of survival. However, treatment guidance iPET is not yet recommended for DLBCL clinical practice. We aimed compare the value when utilizing visual Deauville 5-point scale (DS) semiquantitative variation maximum standardized uptake (ΔSUVmax).We included 85...
Natural killer (NK) cells are a very important component of the innate immune response involved in lysis virus infected and tumor cells. Aging has profound impact frequency, phenotype function NK Chronic Myeloid Leukemia (CML) caused by BCR-ABL gene formation encoding aberrant oncoprotein tyrosine kinase. Treatment with kinase inhibitors (TKIs) induces durable deep molecular response. The to treatment life expectancy is lower older patients chronic phase CML than younger patients. In this...
Introduction: Interim response evaluation by PET (iPET) in diffuse large B cell lymphoma (DLBCL) is encouraged to rule out disease progression and has been suggested be predictive of survival. However, treatment guidance iPET not yet recommended for DLBCL clinical practice. We aimed assess the value free survival (PFS) overall (OS) patients (pts). Methods: Single centre retrospective analysis pts diagnosed with from 2010 2019, uniformly treated R-CHOP/R-CHOP-like protocols (6-8 cycles)...
Background: Autologous hematopoietic stem cell transplantation (ASCT) is the current standard of care for younger patients (pts) with multiple myeloma (MM), improving overall survival (OS) and progression free (PFS). According to EBMT, use chemotherapy, typically cyclophosphamide (Cy), in combination granulocyte colony-stimulating factor (G-CSF) preferred strategy (HSC) mobilization peripheral blood (PB). However, major disadvantages are therapy-related toxicity higher failure. Plerixafor...
Figure 1: ROC curve for PNI in predicting progression-free survival and Overall according to CONUT scores. Background: Several recent studies have shown the clinical significance of poor nutritional status accessed by Prognostic Nutritional Index (PNI) Controlling (CONUT) on patients (pts) with solid hematological malignancies, but its impact classical Hodgkin lymphoma (cHL) is not established. Aim: To evaluate prognostic value baseline cHL. Methods: Retrospective analysis adult pts cHL,...
Figure 1: PFS and OS for both IPS-3 IPS-7 scores Introduction: The survival of patients (pts) with classic Hodgkin Lymphoma (cHL) has been significantly increased due to refinement therapeutic strategies. International Prognostic Score (IPS-7) is the most used risk stratification tool advanced-stage cHL but it may have decreased prognostic value in pts treated contemporary era. A novel scoring system, IPS-3, comprising three seven indicators (age ≥45, stage IV, haemoglobin <105 g/L), was...
Introduction: The prognostic impact of body mass index (BMI) in diffuse large B cell Lymphoma (DLBCL) patients is controversial, as some studies showed a survival benefit for higher BMI while others no correlation or even detrimental effect on survival. On the other hand, regarding nutritional status outcome have shown that lower Prognostic Nutritional Index (PNI) scores are related to Progression Free Survival (PFS) and Overall (OS). Aim: Evaluate PNI at diagnosis OS PFS cohort with DLBCL,...
Introduction: Bone marrow assessment (BMI) is an important part of disease staging in lymphoma, and includes FDG18-PET BM trephine biopsy (BMB), which the gold-standard for detecting infiltration. Nevertheless, studies indicate that PET accurately detects BMI aggressive lymphomas. We aimed to assess accuracy diffuse large B-cell lymphoma (DLBCL). Methods: Single centre retrospective analysis 335 patients (pts) diagnosed with DLBCL from 2010 2019. BMB data at diagnosis was available 144 pts....
Introduction: Diffuse Large B Cell Lymphoma (DLBCL), the most common non-Hodgkin lymphoma, despite having a standard of care treatment (R-CHOP), has heterogeneous clinical and molecular features. The widely used risk scores are based on biochemical parameters, which can underestimate impact genomic signatures. Recognizing score with better discriminative power might be important to identify high-risk group, for whom R-CHOP may insufficient. We aim compare prognostic efficacy in DLBCL: IPI...
Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and more frequent in elderly patients (pts), which have a worse prognosis than younger patients. This partially explained by existence comorbidities poor performance functional status, limiting use R-CHOP as standard therapy. We aim to evaluate impact clinical factors therapeutic decisions outcomes DLBCL pts. Methods: Retrospective analysis >65 years pts with DLBCL, NOS diagnosed our center,...
Background: During the past few years, several studies have tried to identify biomarkers that could improve current prognostic assessment in diffuse large B-cell lymphoma (DLBCL). Neutrophil/Lymphocyte Ratio (NLR) and Monocyte/ Lymphocyte (MLR) are simple, cost-effective readily available tools may a significance DLBCL treated with R-CHOP, according some studies. Aims: To determine value of NLR MLR DLBCL, Not Otherwise Specified (NOS). Methods: Retrospective analysis 335 patients (pts) newly...